1-3 of 3
Norman M. Padre
Close
Sort by
Journal Articles

AC220, a Potent, Selective, Second Generation FLT3 Receptor Tyrosine Kinase (RTK) Inhibitor, in a First-in-Human (FIH) Phase 1 AML Study.

Jorge Cortes, MD, James Foran, MD, Darejan Ghirdaladze, MD, PhD, Marcel P DeVetten, MD, Mamia Zodelava, MD, PhD, Peter Holman, MD, Mark J Levis, MD, PhD, Hagop M Kantarjian, MD, Gautam Borthakur, MD, Joyce James, PhD, Patrick P Zarringkar, PhD, Ruwanthi N Gunawardane, PhD, Robert C Armstrong, PhD, Norman M Padre, Wendell Wierenga, PhD, Robert Corringham, MD, Mohit Trikha, PhD
Journal: Blood
Blood (2009) 114 (22): 636.
https://doi.org/10.1182/blood.V114.22.636.636
Published: 2009
Journal Articles

Phase 1 AML Study of AC220, a Potent and Selective Second Generation FLT3 Receptor Tyrosine Kinase Inhibitor

Jorge E. Cortes, Darejan Ghirdaladze, James M. Foran, Marcel P. DeVetten, Mamia Zodelava, Mark J. Levis, Norman M. Padre, James Joyce, Patrick P. Zarrinkar, Robert Corringham
Journal: Blood
Blood (2008) 112 (11): 767.
https://doi.org/10.1182/blood.V112.11.767.767
Published: 2008
Journal Articles

Human Pharmacokinetics of AC220, a Potent and Selective Class III Receptor Tyrosine Kinase Inhibitor.

Jorge Cortes, James M. Foran, Marcel P. Devetten, Francis J. Giles, Joyce James, Patrick P. Zarrinkar, Michael H. Silverman, Kerry A. Kelly, Norman M. Padre, Shripad Bhagwat, Wendell Wierenga
Journal: Blood
Blood (2007) 110 (11): 1597.
https://doi.org/10.1182/blood.V110.11.1597.1597
Published: 2007